Page 138 - 《中国药房》2024年4期

and subsequent reintroduction of trastuzumab：activity and [48] KIM D W，MEHRA R，TAN D S W，et al. Activity and
tolerability in patients with advanced human epidermal safety of ceritinib in patients with ALK-rearranged non-
growth factor receptor 2-positive breast cancer[J]. J Clin small-cell lung cancer（ASCEND-1）：updated results from
Oncol，2012，30（14）：1594-1600. the multicentre，open-label，phase 1 trial[J]. Lancet Oncol，
[36] MARTIN M，HOLMES F A，EJLERTSEN B，et al. Nera‐ 2016，17（4）：452-463.
tinib after trastuzumab-based adjuvant therapy in HER2- [49] PETERS S，CAMIDGE D R，SHAW A T，et al. Alectinib
positive breast cancer（ExteNET）：5-year analysis of a ran‐ versus crizotinib in untreated ALK-positive non-small-cell
domised，double-blind，placebo-controlled，phase 3 trial lung cancer[J]. N Engl J Med，2017，377（9）：829-838.
[J]. Lancet Oncol，2017，18（12）：1688-1700. [50] BRONTE E，BRONTE G，NOVO G，et al. Cardiotoxicity
[37] MURTHY R K，LOI S，OKINES A，et al. Tucatinib， mechanisms of the combination of BRAF-inhibitors and
trastuzumab，and capecitabine for HER2-positive meta‐ MEK-inhibitors[J]. Pharmacol Ther，2018，192：65-73.
static breast cancer[J]. N Engl J Med，2020，382（7）： [51] BURGER J A，TEDESCHI A，BARR P M，et al. Ibrutinib
597-609. as initial therapy for patients with chronic lymphocytic
[38] GOETZ M P，TOI M，CAMPONE M，et al. MONARCH leukemia[J]. N Engl J Med，2015，373（25）：2425-2437.
3：abemaciclib as initial therapy for advanced breast cancer [52] SHARMAN J P，EGYED M，JURCZAK W，et al. Acala‐
[J]. J Clin Oncol，2017，35（32）：3638-3646. brutinib with or without obinutuzumab versus chlorambu‐
[39] SLAMON D J，NEVEN P，CHIA S，et al. Overall survival cil and obinutuzumab for treatment-naive chronic lympho‐
with ribociclib plus fulvestrant in advanced breast cancer cytic leukaemia（ELEVATE TN）：a randomised，con‐
[J]. N Engl J Med，2020，382（6）：514-524. trolled，phase 3 trial[J]. Lancet，2020，395（10232）：1278-
[40] FINN R S，MARTIN M，RUGO H S，et al. Palbociclib 1291.
and letrozole in advanced breast cancer[J]. N Engl J Med， [53] GOLAN T，HAMMEL P，RENI M，et al. Maintenance
2016，375（20）：1925-1936. olaparib for germline BRCA-mutated metastatic pancrea-
[41] VERMA S，MILES D，GIANNI L，et al. Trastuzumab em‐ tic cancer[J]. N Engl J Med，2019，381（4）：317-327.
tansine for HER2-positive advanced breast cancer[J]. N [54] GONZÁLEZ-MARTÍN A，POTHURI B，VERGOTE I，et
Engl J Med，2012，367（19）：1783-1791. al. Niraparib in patients with newly diagnosed advanced
[42] MODI S N，SAURA C，YAMASHITA T，et al. Trastu‐ ovarian cancer[J]. N Engl J Med，2019，381（25）：2391-
zumab deruxtecan in previously treated HER2-positive 2402.
breast cancer[J]. N Engl J Med，2020，382（7）：610-621. [55] SCHNEIDER B J，NAIDOO J，SANTOMASSO B D，et
[43] BARDIA A，MAYER I A，VAHDAT L T，et al. Sacitu‐ al. Management of immune-related adverse events in pa‐
zumab govitecan-hziy in refractory metastatic triple- tients treated with immune checkpoint inhibitor therapy：
negative breast cancer[J]. N Engl J Med，2019，380（8）： ASCO guideline update[J]. J Clin Oncol，2021，39（36）：
741-751. 4073-4126.
[44] LI Z，XU H，YU L，et al. Patient-derived renal cell carci‐ [56] GARUTTI M，NOTO C，PASTÒ B，et al. Nutritional ma-
noma organoids for personalized cancer therapy[J]. Clin nagement of oncological symptoms：a comprehensive re‐
Transl Med，2022，12（7）：e970. view[J]. Nutrients，2023，15（24）：5068.
[45] UNVERZAGT S，MOLDENHAUER I，NOTHACKER [57] FRANCISCO D M A，ZHANG L L，JIANG Y，et al. Risk
M，et al. Immunotherapy for metastatic renal cell carci‐ factors associated with severe Clostridioides difficile
noma[J]. Cochrane Database Syst Rev，2017，5（5）： infection in patients with cancer[J]. Infect Dis Ther，2023，
CD011673. 12（1）：209-225.
[46] JERUSALEM G，DE BOER R H，HURVITZ S，et al. [58] HUANG L，YE X H，WU F Q，et al. Study of prevalence
Everolimus plus exemestane vs everolimus or and risk factors of chemotherapy-induced mucositis in ga-
capecitabine monotherapy for estrogen receptor-positive， strointestinal cancer using machine learning models[J].
HER2-negative advanced breast cancer：the BOLERO-6 Front Oncol，2023，13：1138992.
randomized clinical trial[J]. JAMA Oncol，2018，4（10）： [59] ANDREYEV J，ROSS P，DONNELLAN C，et al. Gui-
1367-1374. dance on the management of diarrhoea during cancer che‐
[47] KHOZIN S，BLUMENTHAL G M，ZHANG L J，et al. motherapy[J]. Lancet Oncol，2014，15（10）：e447-e460.
FDA approval：ceritinib for the treatment of metastatic （收稿日期：2023-08-29 修回日期：2024-01-24）
anaplastic lymphoma kinase-positive non-small cell lung （编辑：孙 冰）
cancer[J]. Clin Cancer Res，2015，21（11）：2436-2439.

· 512 · China Pharmacy 2024 Vol. 35 No. 4 中国药房 2024年第35卷第4期